Blocking CXCL1 reduces the migration of MDSCs, TAMs, and Tregs to the tumor, thus significantly alleviates the highly immunosuppressive microenvironment of GBM and leads to the high aggregation of CD8+ T cells, thereby reactivating the anti-tumor immune response against GBM [39]. This evidence concerns the gene CD8A and neoplasm.